Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Hua Medicine ( (HK:2552) ) is now available.
Hua Medicine has scheduled a board meeting for March 26, 2026 to review and approve the group’s audited final results for the financial year ended December 31, 2025. At the same meeting, directors will also consider whether to recommend a final dividend and may address other corporate business, signaling an upcoming disclosure of the company’s annual performance and potential shareholder returns.
The most recent analyst rating on (HK:2552) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Hua Medicine stock, see the HK:2552 Stock Forecast page.
More about Hua Medicine
Hua Medicine is a biopharmaceutical company listed in Hong Kong under stock code 2552, incorporated in the Cayman Islands with limited liability. The group focuses on developing and commercializing innovative medicines, with operations overseen by a board comprising executive, non-executive and independent non-executive directors.
YTD Price Performance: 5.52%
Average Trading Volume: 3,479,641
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.16B
See more data about 2552 stock on TipRanks’ Stock Analysis page.